BSEM (BioStem Technologies) ROIC %: 11.84% (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.55
GF Value $139.96
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies ROIC %?

BioStem Technologies BSEM +3.20% 49 ROIC % is 11.84% as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. BioStem Technologies's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2025 was 11.84%.

As of today (2026-06-26), BioStem Technologies's WACC % is 6.61%. BioStem Technologies's ROIC % is 46.33% (calculated using TTM income statement data). BioStem Technologies generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


BioStem Technologies  (OTCPK:BSEM) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BioStem Technologies's WACC % is 6.61%. BioStem Technologies's ROIC % is 46.33% (calculated using TTM income statement data). BioStem Technologies generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


BioStem Technologies ROIC % Related Terms


BioStem Technologies ROIC % Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies ROIC % Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.21 -29.15 -82.03 -120.02 209.02

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.63 -15.49 273.02 184.74 11.84

BSEM vs TCRX, BYSI, MCRB: ROIC % Comparison

For the Biotechnology subindustry, BioStem Technologies's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's ROIC % distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's ROIC % falls into.


BSEM
49GF Score
BioStem Technologies Inc BSEM
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies ROIC % Calculation

BioStem Technologies's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROIC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=31.201 * ( 1 - 0% )/( (6.705 + 23.149)/ 2 )
=31.201/14.927
=209.02 %

where

BioStem Technologies's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2025 is calculated as:

ROIC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=5.796 * ( 1 - 48.2% )/( (23.149 + 27.581)/ 2 )
=3.002328/25.365
=11.84 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 11.84% mean?
BioStem Technologies (BSEM) has a ROIC % of 11.84% as of Sep. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' ROIC % too high?
BioStem Technologies' current ROIC % is 11.84%. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' ROIC % compare to TCRX and BYSI?
BioStem Technologies' ROIC % of 11.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current ROIC % is 11.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.55 — trading 97.5% below its estimated fair value. The current ROIC % is 11.84%. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current ROIC % is 11.84% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.55 is trading 97.5% below its estimated GF Value™ of $139.96. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • ROIC %: 11.84%
  • GF Value™: $139.96 vs. price of $3.55 (97.5% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$139.96
GF Value